Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1459-1470

  Kwong, Lawrence N ^a   Boland, Genevieve M ^a   Frederick, Dennie T ^b   Helms, Timothy L ^a   Akid, Ahmad T ^a   Miller, John P ^a   Jiang, Shan ^a   Cooper, Zachary A ^a   Song, Xingzhi ^a   Seth, Sahil ^a   Kamara, Jennifer ^a   Protopopov, Alexei ^a   Mills, Gordon B ^a   Flaherty, Keith T ^b   Wargo, Jennifer A ^a   Chin, Lynda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; BIM PROTEIN; CASPASE 7; CYCLIN B1; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; BRAF PROTEIN, MOUSE; DOXYCYCLINE; IMIDAZOLE DERIVATIVE; OXIME; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, MOUSE; TAMOXIFEN; TUMOR PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL LINE; MIDDLE AGED; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RNA SEQUENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION; UPREGULATION; YOUNG ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; MELANOMA, EXPERIMENTAL; METABOLISM; PHYSIOLOGY; TRANSGENE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXYCYCLINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM PROTEINS; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; TAMOXIFEN; TRANSGENES;

EID: 84926332167     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78954     Document Type: Article

References (50)

1. McArthur GA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-332.
2. Ascierto PA, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205-3211.
3. Grob JJ, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: qualityof-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol. 2014;25(7):1428-1436.
4. Quintyne KI, Baker S, Wallis F, Gupta R. Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma. BMJ Case Reports. 2012;2012:bcr1120115202.
5. Ponti G, Tomasi A, Pellacani G. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol. 2012;5(1):60.
6. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
7. Wagle N, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4(1):61-68.
8. Shi H, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80-93.
9. Wagle N, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096.
10. Shi H, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4(1):69-79.
11. Van Allen EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4(1):94-109.
12. Rizos H, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20(7):1965-1977.
13. Nakamura A, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013;73(23):7043-7055.
14. Morris EJ, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3(7):742-750.
15. Carlino MS, et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol. 2014;8(3):544-554.
16. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-920.
17. Atefi M, et al. Reversing melanoma crossresistance to BRAF and MEK inhibitors by cotargeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973.
18. Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2012;25(2):248-258.
19. Villanueva J, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
20. Jeong JH, et al. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS ONE. 2008;3(12):e3949.
21. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85(1):27-37.
22. Zheng H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455(7216):1129-1133.
23. Bosenberg M, et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis. 2006;44(5):262-267.
24. Kwong LN, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10):1503-1510.
25. Palomero T, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210.
26. Shi H, et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
27. Corcoran RB, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013;5(196):196ra98.
28. Boussemart L, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014;513(7516):105-109.
29. Wood KC, et al. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal. 2012;5(224):rs4.
30. Johannessen CM, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-972.
31. Sun C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118-122.
32. Agarwal R, et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009;15(11):3654-3662.
33. Caudle AS, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(11):1821-1828.
34. Long GV, et al. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 2013;26(4):499-508.
35. Wilmott JS, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAFmutant melanoma patients during BRAF inhibitor treatment. J Immunol. 2014;192(5):2505-2513.
36. Bogunovic D, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A. 2009;106(48):20429-20434.
37. Mandruzzato S, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med. 2006;4(1):50.
38. Mann GJ, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol. 2013;133(2):509-517.
39. Harbst K, et al. Molecular profiling reveals lowand high-grade forms of primary melanoma. Clin Cancer Res. 2012;18(15):4026-4036.
40. Du J, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotech. 2009;27(1):77-83.
41. Luckert K, et al. A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins. Sci Signal. 2012;5(206):pl1.
42. Das Thakur M, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251-255.
43. Abdel-Wahab O, et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies. Cancer Discov. 2014;4(5):538-545.
44. Wilson TR, et al. Widespread potential for growthfactor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505-509.
45. Straussman R, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-504.
46. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-1134.
47. Duncan JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149(2):307-321.
48. Belteki G, et al. Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 2005;33(5):e51.
49. Tibes R, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5(10):2512-2521.
50. Torres-García W, et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014;30(15):2224-2226.